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Many haemorrhagic complications: have been attributed to increased 
intravasculal' fibrinolytic activity. The- degradation products: 
resulting from fibrinolysis have been shown to interfere in fibrin 
polymerization and nave been observed in defective clot formationo 
Although considerable knowledge h~ accrued concerning the mecnanism 
of fibrinolysis and tne resulting products. areas of controver,sy and 
intermittent ol)scuri:ty remain. The study presented herein was: 
conducted to resolve. if poss;ible. existing di"screpancies and 
character$ze with. certainty intermediate and end proteolytic products. 
An effort was made to correlate experimental findings; with clinical 
disease states;. 
The products; of serial digestion of fibrinogen by plasmin were 
studied by immunodiffusion. immunoelectrophoresis: and gel exclusion. 
Two products were observed. These products were identified as- the 
D and E fragmenta, originally reported by Nussenweig .!!..!!~ {l960)o 
The D fragment was repr-esented by a band located in the beta area of 
the electrophoretic fieldo This product was: formed early in tbe 
digestion process; and underwent no further degradationo The second 
product. a migrtatoxy band, probably representing a plasmin 
susceptible. precursor of the. E fragment, was initially observed 
within the locus of the D fragment. However, as digestion proptessed 
the band migrated across. the electropboretic field t.o the pre albumin 
area t remaiuing in this position with exhaustive proteolysis" This 
band represent.ed the plasmin resistant & fragment end product. 
Undel' certain experimental conditions the hydl'olysis of fibrinogen 
into the E. fragmen.t may apparently :De reversed. 
Sel'um samples: from 19&, nospitallzed patients were studied fO'l.' 
the presence. of, f~inolytic intermediates and end products. 
Patho~ogic products. were found in 10 of. the 196 samples. Of tbese 
10. aample&, 8 contained D fragments, whereas 2, samples contained 
both the D and :& fr,apenta. Clinical-patbologic correlation 
indicates that demonstl'able fibrinolytic products were associated 
wi th inj ury to the hepatic, renal and vascular systems. The small 
molecular weigbt E fragment was encountered only· in instances of 
renal failure. 
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INTRODUCTION 
Bleeding diathesis secondary to intravascular thranbosis have 
recently been attributed to increased fibrinolytic activity~ 
Fibrinolysis has been defined as the dissolution of the human blood 
clot or fibrin by a proteolytic enzyme; whereas t fibrinogenolysis 
refers to the enzymatic digestion of human f'ibrinogen. 
Accumulati~ knowl~dge concerning a group of naturally 
occuring blood components primarily functioning in, fibrinolysis or 
fibrinogenolysis has greatly facilitated the understanding of the 
fibrinolytic mechanismo The, basic component of this mechanism is 
plasminogen. a proenzyme normally circulating as part of the 
globulin moiety of the plasma proteins. Plasminogen activated to 
plasmin t a proteolytic enzyme, is capable of degrading both 
fibrinogen and fibrino 
The products. resulting from the degradation of fibrinogen and 
~' 
fibrin and the relationship of these products to disease states 
have stimulated considerable interest. Fibrinolytic products and 
fibrin ogen oly tic products appear to be immunologically indist 1n-
guishable and are, therefore, often referred to synonymously as 
fibrinolytic products. The end products of fibrinolysis have been 
defined as: (1) small polypeptide fragments accounting for 
approximately 3Q% of the parent fibrinogen molecule and, (2) two 
large molecular wei~t frasment& accounting fortne remaining 70\0 
Recent studies have focused upon the characterization of the two 
larger molecular weight fragments labelled liD" and "E"., These 
products have been implicat.ed in the inhibition of the enzymatic 
conversion of fibri~ogen to fibrin and appear to account for the 
abnormal clot formation often demonstrated in pet"Sons exh.i.bi ting 
increased fibrinolytic activity., 
2 
A well defined correlation between the products of fibrinolysis 
and the bleeding diathesis often encountered as a result of 
increased fibrinolytic activity haa not been cleaX"ly delineatedo 
Therefore. further studies are needed to elucidate fihX"inolysis. 
the products of fibrinolys.is and the relationship of fibrinolytic 
products to disease., Immunological procedures and other methods 
have been employed to study (.1) the products. of fibrinolysis 
resulting from tbe d.egradation of fibrinogen by commercial plasmin 
and. '-2) the fibrinolytic products appearing spontaneously in the 
serum of hospitalized patientso The results of these studies t 
together with additional findings are presented 0 
REVIEW OF LITERATURE 
I CLOTTING MECHANISM 
In recent years, it has become apparent that the fibrinolytic 
Pl'ocess in man is in a m01"e dynamic state than pI'eviously Ncognized 
and that al}el"rations in its mechanisms may contribute significantly 
to the pa~genes.i.s of disease. Such considuation bas stimulated 
invea~igative: interest that has resulted in an increased number of 
publications. In as much as fibrin formation' is the end product of 
coagulation process, consideration should he' given to the clotting 
mechanism. 
According to Hiale (1967) the clotting process, leading to the 
fibrin clot, is represented by four interdependent phases (see 
Figure 1): Phase I t in which-platelet factor 3 is. released following 
the breakdown of platelets during tbe iuitiatOP or'contact reaction; 
Phase II, in wbich plasma. thl"omhoplastin is formed; Phase III, in 
which thrombin is, formed from, prothrombin; and' Phase IV, in which 
fibrin is fomed from. fibrinogen. Many' workers. pNfel" to combine 
Phase I and Phase Il. since hoth phases l'es.u~t in the genel'ation of 
thromboplastin. Potential %'esources. for thromboplastin are the 
blood {intrinsicl and .tbe.~tis.sues.,'e.x:trin&ic) (Seegers, 1962). 
Phase I and II involve the generation of intrinsic thrombo-
plastin from factors X'eadily- available in the blood. Following 
contact with a fONign surface inactive Hageman factor (.factor XII) 
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4 





------ PLASMA THROMBOPLASTIN CT",olftbi"~ 
[
INHIII TOR: J 
FACTOR X 
PHASE .m: THROMBOGENESIS 
T"rombopIO.,jft 











INHIIITOR : J 
ANTITHROM81N (S) 
FIBRINOGEN --"i'""-- FIBRIN 




Fig. 1. Schematic representation of the process of 
blood coagulation. The division into 4 phases is 
arbitrary and is used only as a convenient scheme for 
classifying the hemorrhagic disorders and the tests 
used to study them. (Miale, 1967) 
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is CODvertedto itaactiva fOl'ln. The. activation of factor XII is 
followed by tne activation afplasma thromooplastin antecedent (PTA 
or factor XI). In the presence of this product, plasma tbrOll'Jbo-
plastin component (,pTe. or factor IX) is changed to its active form. 
Activated factor IX reacts with- antihemopnilfac . factor (AHF or 
factor VIII)., Stuart-h-ower factor 'factor X) and ionized calcium 
(.factor IV) to form a suilstance called intermediate. product I. 
Intermediate product,! reacts with-platelet pbospholipid to form 
intermediate pl"oduct II. Finally, intermediate product II combines 
wi tb proaccelerin ,Uabile:factor.OI'. f·actor V). to .. form intrinsic 
lllood tbromboplastin '-Rodman,. 19.68}.. The generati.on of intrinsic 
thromboplastin is complex, time con$uming and usually involves 
about 60\' of the total time required. for coagulation. An altemate, 
more rapid route to clot formation occurs following injury to 
tisaues. whereby blood is. exposed to body tissues rich in intrinsic 
thromboplastin. 
Prothrombin is an' alpha globulin produced .in the liver , 
requiring vitamin l.{ for its,_ synthesis, jID.~ is consumed during the 
clotting process.. One. molecule of prothromlJinprobabl.y yields two 
molecules. of .thrombin, '-Rodman, liS 8 ).. Activated, purif!ad 
protbroml.j)in yields.thromin-at a concentration of about 2,70.0 unitslmg 
of dry material. Estimates indicate the concentration of prothrombin 
in nonnal plasma .is ahout 12 mg/100 ml (Seegers, 1967). 
The activation. of prothrombin t then, results in the formation 
6 
of thrombin, a highly specific esterase (McKay'~ 1965} 0 This: enzyme 
acts upon the fibr~nogen molecule to produce the resultant fibrin 
monomer. Fibrinogen {.factor I ~ is a plasma protein normally present 
at concentrations of '300. to SOO mg/100 ml plasma (Quick. 1966)0 The 
molecular weigh-t of this protein in man has been estimated at 350,000 
(Schultze, 1966)" Electron micrographs have been obtained of the 
shadow cast bovine fibrinogen molecule establishing the general 
mOl'phology and dimensions in the dry state (see Figure 2).. The 
molecule consists of a linear arra:y of three nodules held together 
by a very tbin thread~ The two end nodules are alike. but the 
center one is slightly small8%'," When polymerization occurs, the 
fibl'inogen molecule is altered 'see Figure 3). Electron microgl'sphs 
of fibrin indicate the fibrinogen molecule shrinks in length during 
the fibrinogen-fibrin conversion. The cross bands binding the 
fibrinogen molecules together are also apparent (Jiall and Slayter, 
1955l). 
Using fluorescent antibody techniques, Forman' and Barbard (1964) 
have shown that fibrinogen is synthesized in the Ii vel' and have 
identified the liver parenchymal cells, as the exact site of 
production. Fibrinogen is formed in the liver at a rate governed 
by its concentrati.OD in plasma" ,When circulating fibrinogen levels 
are depressed .... synthesis can be enhanced by as much as eigb.t times 
the normal rate~ Fibrinogen and fibrin are' eanposed of six peptide 
chains 'see Figure 4). During the conversion' of fibrinogen to tbe 
o 
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Fig -- 2. A structural model of" tin:! fibrinaqenll\Cre:C1"a-Ie: base-don data 
derived from eie'Ctron in±cro~opi-c' antl-other- p'hys-icochemical observations. 
(H'al1. and8:iayter, 1959) 
"'-J 
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Ii 240 A ... ~ 
Fig. 3. Model of fully polymerized fibrin molecule. (Hall and Slayter, 1959) 
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Fig. 4. A schematic drawing o£~the, :t:axnd.~ :.ain±uoacid-:r.eS±dttes." on't:he'p-eptide 
chains of fibrinogen fractions isolated from human plasma. The action of thrombin 
produces fibrin with identical terminal amino acid residues. The end groups found 
on the polypeptide chains include alanine (Ala), tyrosine (Tyr), glycine (Gly), 
and unidentified amino acid groups (0). (Adapted from Searcy, 1969) 
\0 
fibriD mcnomer, foUX' of the teminal amino acid :residues in 
fibrinogen are replaced wi'tll glycine {Searcy, 1969}. During the 
action of thrombin. ~gi.nyl-glycine bonds are disrupted in the 
fihr~ogen molecu.le: aDd paptides are separated from the molecule 
{Gladnv at a1., 196.41. This action causes a loss of negative 
--
10 
cnarges frOID tIle remaining fibrin monaners. Polymerization of the 
molecules occursbf electrostatic attraction. Fibrinogen-fibrin 
conversion takes place in stages and depends on environmental 
conditions such as pH and ionic strength. The fibrin monomers fil'St 
form an intermediate polymer i:Jy lining up' end t.o end. These 
polymers then line' up side to side to f'orm the subsequent course 
fibrin strands Uaatallo et. a1.. 1962al .. 
--
In 196Q, Laki !l.!!:, suggested that the tbrombin ... induced 
conversion of fihrinogen to fibI'in clot., is a' two phase process: 
first, an enzyme. action modifying fibrinogen ·to. fibrin. and second, 
the cross linkage of fibrin molecules. 
Lorand and Jacobsen '-19S8) have described a factor known as the 
fibrin stabilizing factor' (rsr). These investigators contend that 
the naturally occurri:og insoluble fibrin clot is a co-polymer of 
fibrin and the fibrin stabilizing factor. These workers demonstrated 
that when fibrinogen, is clotted. ~.vitro.by thrombin in the pI'esence 
of calcium ions and fibrin stabilizing factor a clot is formed 
resembling the fibrin clot formed!2.,!!.!.2,. In the absence of fibrin 
atabiU.zing factor, a .. , mechanically weaker' clot is formed that can he 
11. 
dissolved in 5M urea or monochlol'acetic acid. 
Upon further s.tudy t Lorand (19i5) suggested that tbe enzyme. 
thrombin.·baa a dual role in catalyzing two overlapping reactions. 
The first ~action inducest.be polymerization of fil)rinogen t and 
the second activates the fibrin stabilizing factor causing cross-
linkage of the fibrin molecule, thus supplying the" stabilizing 
effect. 
Nussbaum and Morse (.1904) determined the fibrin stabilizing 
factor (FSF) aotivity in the plasma of patients with various disease 
states. These investigators found diminished fibrin stabilizing 
factor actlvity in ZS of 86 patients wi tb 11 vel' disease, 16 of which 
had severe cirrhosis in the tennin.al pbase of the disease. 
Diminished FSF activity was also found in 21 of 28 patients with 
metastasestotbe liver. 
Other workers (Alimi et '. a1., 1968) have., shown that f !brin clots 
--
formed in the presence of fibrin stabilizing factO%', Factor XIII, 
are more resistant to plasmin and other lytic enzymes than clots 
formed in tbe absence of Factor XIII. These workers also noted 
reduced fibrin stabilizing factor activity in patients with liver 
4isease. suggesting 'that Factor XIII may be synthesized in the liver .. 
II FIBRINOLYSIS 
The process of fibl'in clot digestion is called fibrinolysis. 
Fibrinolysis undoubtedly Npresents an important mechanism in the 
12 
maintenance of the in't:ep"ity of the vascular lumen (McKay, 1965) • 
T11e dissolution of human blood clots bas been reported in the 
literature as • .-ly as 179-4, but. It. was not. until 1905 that Nolf t 
ODe of the great pioneers iD blood coagulation,. introduced tbe view 
that fibrinolysis was due to a proteolytic "enzyme in plasma, and 
that indeed the coagulation process itself· was of a proteolytic 
~igin. with fibrinolysis repNSenting the end stages of the pX'Ocess. 
Later, Ratnolf (lQS5) modified Nolf's concept by suggesting that the 
fibrin proteolytic activity of plasma is activated simultaneously 
with the clott~ process, thus pennitting the destruction of fibrin. 
It is now,. however., geDerally agreed that tile processes involved in 
clotting are. distinct from those involved in fibrinolysis (Sherry 
and Alkjaersig,19S7).. A review of current concepts concerning 
fibrinolytic mechanisms" -follaws. 
Fibrinolysis is. contl'ol1ed in vivo by anenz.ymati.c process .. 
--
This process" involves. the conversion of the proenzyme, plasminogen, 
(.143.00Q molecular weight). into a proteolyti.c enz.yme, plasmin 
(molecular wei.gb.t l08,flOG1. Plasmin:ogen normally circulates in an 
inacti.ve form as part of tb~ globulin moiety of the plasma proteins 
'-Radman. 196.8l. When plasminogen is converted to the proteolytic 
enzyme, plasmin, soluble pept.ide fragments are released (Alkjaersig 
et al. t 1958a1. Actlvated plasminogen or plasmin was origiDally 
--
called f ibl'inolysin, but it bas heen demonstrated to be a potent 
proteolytic enzyme l'esemDifDg pepsin. This enzyme can digest a bost 
13 
of protein sullatancea including fihrinog8ll,fUrin, FactOl' V. 
FactOI' VIII. some components of complement, corticotropin, growth, 
hormone and glucagon.. Addi"tioaal protein subsuates hydX'olyzed by 
plasm.in and used for asaayi.ngplastnin are:, casein •. -gelatin, beta-
lactoglobulin. azocal, Md. power and protamina complexes. (.Fletcher 
et al •• 1962a. ShelTy et .al •. , 19&6). Although generated plaSmin can 
-...... ----
participate .in at least three distinct reactions, pb.ysiologically 
the lytic action upon fibrin is favored (see Figure 5).. Fibrin is 
capable of competing with antiplasmins for plasmin. The latter 
attacks proteina other than fibrin as previ.ously described, but only 
when t,he lytic factor is produced in great excess (Searcy. 1969). 
The conversion of plaaminogen to plasmin is' an enzymatic 
"action rnedia'ted Ji)y activatOl' substances called kinases. Many 
tissues of the body .• particularly vascular intima. lung. pancreas, 
and prostate contain activator sullstances capable of splitting tne 
inactive plasminogen from the globulin molecule and converting it to 
its active form, plasmin 'Rodman, 1968l. Activators,' as des:cribed 
today. were originally considered to be. fibrinolysins. These 
fibrinolysins were first demonstrated in certain strains of hemolytic 
streptococci and later. correlated with the activation of tbe 
proen~ plasminogen. 
A substance from, filtrates of broth, cultures of certain strains 
of hemolytic streptococci. capable of inducing rapid fibrinolysis of 
human blood clots- was f 1r8t oiserved by Tillett and Garner in 1933. 
PLASM'INOGEN 
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Thi$ substance tIlatl named streptococcal fiDXtinolysin. Later, Milstone 
(19.41) demon&trated that the streptococcal fibXtinolysin would not 
lyse thl'ombin induced fibrin clots when the subs,trate was' highly 
purified human fibrinogen. Milstone noted, however, that if a small 
amount of euslohulin waa added from human seXtum, rapid lysis of the 
clot resulted. Milatone named this substance the plasma lysinS 
factor and reported that it interacted with s'treptococcal fibrfne-
lysin to form an active lysing system. Later, ot.her worKers (,Kaplan, 
19.44; Christenaen,19.4S1 showed that the plasma euslobulin which 
Milstone had described was an inactive precursors (plasminogen) of a 
proteolytic enzyme (plasmin) which was rapidly activated by &tXtepte-
coccal fibrinolysin. CbXtistensen (1945) suggested that since tbe 
streptococcal substance was not a fibrinolysin, but instead an 
activator, that streptococcal fibrinolysin be.Xtenamed streptokinase. 
To date, plasminogen activator bas been.found in the plasma 
(plasma activator) of v8l'ious tissues, as well as in the urine 
(urokinase). Alkjaersig !1.!!.., (1958b) demonstrated that plasminogen 
is activated by uXtokinase, streptokinase, trypsin an.d autocataly-
tically by plasmin. Although the possible identity 01' the 
relationship of these act! vators ispr.esent,ly unknown, r letcher 
et al., (1962a) suggested that urokinase may represent excreted 
--
plasma activator .and that a similarity exists between tissue activator-
and urokinase. This observation led to the theory tbat tissue 
activator is the primary source, that plasma activator is its pXtoduct 
16 
and that urokinase is its excretion form. Mullertz (1955) maintains 
there is evidence that streptokinase does not react directly with 
plasminogen, instead a chain reaction is initiated. Plasminogen 
interacts with a "proactivator", which is converted to an activator, 
which in turn catalyzes the plasmi~ogen-plasmin reaction. 
Numerous studies have been performed to characterize the plasmin 
activator. Troll and Sherry (1955) have shown that the activation of 
human plasminogen by streptokinase involves two steps: first, the 
stoichiometric interaction of streptokinase with a plasma activator; 
and second, the enzymatic activation of plasminogen by this activator. 
A,lkjaersig ~ al.(l959b) investigated the respective roles of 
plasminogen activators and plasmin by means of test systems using 
1311: labeled clots containing various concentrations of plasminogen. 
Other studies on plasminogen activators in human plasma clots indicate 
that the quantity of plasminogen activators varies in response to 
stress, drug administration, and disease (Alkjaers.ig et !.!.., 1959a; 
Sawyer et al., 1960a; Sherry, 1959b). Further studies, Sawyer ~~., 
1960b; Beck and Jackson, 1966, have compared the effects of plasminogen 
activators and proteolytic enzymes on fibrinolysis. These investigators 
discovered that plasminogen activators added to a fibrin clot would 
initiate the lysis of more fibrin per unit fibri~ogen than the addition 
of either plasmin or trypsin. 
A counter effect to proteolysis is evident in the competition for 
plasmin by antiplasmin (see Figure 5). Inhibitors of plasmin are found 
17 
in the circulating blood as well as in other tissues. McFarlane and 
Bi.ggs (1948) found plasmin inhibitors in saline extracts of human 
liver, kidney, spleen, adrenal, thyroid, muscle, lung, heart, and 
brain. Fletcher ~~. (1959a) showed that the concentration of 
plasma antiplasmin ave~ages approximately five casin inhibitory units 
per milliliter and exceedstheplasmi~ogen content of plasma, which 
is 3.8 casein units per milliliter. Gallimore and Shaw (1967) 
demonstrated plasmi~ inhibitors in serum by studying the lysis of 
fibrin clots prepared from plasminogen-deficient fibrinogen. In a 
system containing no plasminogen, the clot lysis time was inversely 
proportional to the concentration of added plasmin. When serum was 
included, a reduction of reciprocal lysis time resulted, the extent 
of which varied linearly with the amount of serum added. 
Recently, Jacobson (1968a) demonstrated other controls of plasmin 
inactivators in his description of a modified caseinolytic method to 
measure the proteolytic activity in plasma. His studies indicated 
that in normal populations there was a l~rge variation between 
individual plasma samples, probably due to plasminogen-plasmin levels. 
Of significance was the variation produced as a result of hormone 
influence. Increased proteolytic activity was found in pregnant women 
and women receiving oral contraceptives. 
Further studies (Jacobsen, 1968b) were made concerni.ng 
"proteolytic capacity" (i.e. the maximal proteolytic activity that can 
be generated in plasma with the inhibitors present) in several persons 
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of the same family • These studies s.ll:ggested that the property of 
"low proteolytic capacity" was inherited as an autosomal dominant 
trai t. However, no clear cut inheritance could be found concerni.ng 
the property of Ith:igh proteolytic capacity". 
III DEGRADATION PRODUCTS OF FIBRINOGEN 
Godal and Helle (1963) compared the influence of fibrinogenolytic 
and fibrinolytic products in the last st.ages of coagulation and 
reported that fibrinogen breakdown products prolo.ng the thrombin time 
of plasma more effectively than the breakdown products of fibrin. 
However, this may be an erroneous assumption. Hirsh ~2.!. (1965) 
compared the proteolysis products of fibri~ogen and of fibrin and 
found no qualitative or quantitative differences in their actions. 
From these studies it would appear that dist~nguish~ng fibrinogen 
breakdown products from the breakdown products of fibrin is difficult. 
Later work by Beller and Mak, (1967) indicated that proteolytic 
products derived from fibri~ogen are immuno~ogically indistinguishable 
from the proteolytic products of fibrin. 
During the past decade, ~ great deal of research has been done 
in an effort to characterize·the'proteolytic products of fibrinogen. 
Nussenwieg and co-workers (1960) described at least four antigenic 
. groups resulti.ng from plasmin proteolysis of fibrinogen. Fletcher 
.!! al. (1962) s.u.ggested that- only two of the four fractions ( D and 
E located in the alpha-beta electrophoretic regions) are antigenically 
reliable, i.e., demonstrable immunologically. During plasmin 
19 
digestion, intermediate breakdoWn products are formed, but the end 
result is plasmin-resistant fragments. 80me of the plasmin-resistant 
fragments contained the'an~igenic Group D and some Group E. Other 
smaller fragments exhibited nO'an~igenic qualities, Jamieson (1963) 
suggested that the two la,rger fragments (D and E) are aggr,egates of 
these lower molecular weight pieces. 
Other workers have shown by density gradient centrifugation that 
during proteolysis of fibrinogen molecular components were formed 
with respective values of 5.68,6.278, 3.08, and 1.48 (Fischer ~~., 
1963; and Alkjaersig and Fischer, 1964). The two larger fragments 
(D and E) contain individual antigenic determinants that are resistant 
to further action by plasmin. These fragments have been isolated by 
a number of workers using':various techniques: continuous flow paper 
electrophoresis, (Triantaphyllopoulas and Triantaphyllopoulas, 1962); 
gel titration chromat.ography.on 8ephadex(R) (Laursen and Gormsen, 
1967; Nilehn, 1967a); simple radial diffusion, turbidimetric assays 
(Beller' and Maki,1967); immunoelectrophoresis (Lewis and Wilson, 
1964; Nilehn and Nilsson, 1964;'and Nilehn, 1967b) and plasma electro-
phoresis in narrow pore acrylamide, gel (Fletcher, 1965). 
Recently, Kowalski (1968) summarized these studies characterizing 
the physical and immunologic properties of the ~egradation products 
of fibrinogen and proposed a simplified scheme of the reactions 
representing the sequence of events occurri,ng during plasmin 
fibrinolysis. (see Figure 6) Two main groups of products were 
PL F ---.;. x + PPI PL 
-PL- 'PL 
Y + PP2 D + E PP3 ---
F = fibrinogen 
PL = plasmin 
PP = small polypeptides or peptides 
X AND Y ='< 
Fig. 6. Adapted from Kowalski (1968). 




recognized: small polypeptide fragments, soluble in trichloroacetic 
acid (TCA), and high molecular weight fragments. The TCA-soluble 
fragments, formed in the course of fibri~ogen proteolysis by plasmin, 
were released at a steady rate during the reaction. After exhaustive 
proteolysis, these fragments contained about 30 per cent of the total 
nitrogen derived from fibrinogen. The fragments of high molecular 
weight underwent a number of changes leading to the formation of 
several intermediates. These intermediates underwent further proteo-
lysis to form the two fragments referred to by Nussenwieg as "D" and 
"E". (see Table I) Fragment D is thermolabile and has a reported 
molecular weight of 80,000. Fragment E is thermostabile and has a 
molecular weight of 30,000. One mole of fibrinogen (molecular weight 
350,000) during proteolysis yields two moles each of D and E fragments. 
IV EFFECTS OF FIBRINOGEN BREAKDOWN PRODUCTS 
ON CLOTTING 
In 1959b Fletcher !!~. demonstrated that purified fibrinogen, 
partially digested by plasmin, clotted slowly on treatment with 
thrombin, and when added to normal fibrinogen inhibited clotting by 
thrombin. These investigators suggested that the accumulation of 
fibrinogen breakdown products and the development of defective fibrin 
polymers is a significant abnormality, and that the biochemical 
lesion of defective fibrin polymerization may be comparatively common 
and relevant 'to the hemorrhagic complication encountered in many 
diseases. 
Table 1. properties of D and EFractions, 
DEGRADATION MOLECULAR SED IMENTAT I Off , THERMAL 
PRODUCTS' WEIGHT COEFFICIENT PROPERTIES 
D FRAcrrON 80,000 5.6 S THERMOLABILE 




Kopec et ale (1960)· associated fibriD:ogen breakdown products 
with antithrombin activity and su.ggested that an increase of 
degradation products is the·· intermediate cause of delayed clotti.ng. 
These investigators proposed· that the nature of the inhibitory action 
of degradation products may· be two-fold: (1) antithrombin activity 
in the strict sense, i.e~ inhibition of the activity of thrombin; 
and (2) inhibition of the pOlymerization of fibrin monomers. Latallo 
et ale (1962c) further confirmed that fibrinogen proteolysis products 
interfere with fibrinogen-fibrin conversion at the stage of fibrin 
polymerization and gel formation. Alkjaersig et ale (1962) suggested 
that a single large molecular weight fibrinogen fragment, resistant 
to enzymatic digestion by plasmin, is predominantly responsible for 
the inhibition of fibrin polymerization. 
Fibrinogen degradation products appear to influence platelet 
activity as well as fibrin formation. In 1964 Kowalski et ale 
reported that digestion of" platelet rich plasma with streptokinase 
and plasmin diminished the aggregation of platelets. This treatment 
also diminished the adhesive properties of platelets to glass and 
connective tissue fibers (collagen). Platelet aggregation and 
adhesiveness is elicited by thrombin (Kowalski, 1968). Later studies 
(Kopec ~ !!.!.., 1966) indicated that platelet .aggr.egation could also 
be induced by solutions. of fibrinogen preparations; however, the 
addition of fibrinogen degradation products to platelet suspensions 
inhibited fibrinogen-induced aggregation. Jerushalmy and Zucker 
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(1966) dist~nguished.inhibitory effects of early and late products of 
fibrinogen degradation on platelets. These workers have shown that 
early degradation products produced str~nger inhibitory effects on 
platelet aggregation than-late degradation products. 
Release of adenine nucleotides from platelets upon addition of 
thrombin was also found to'be--decreased in the presence of fibrinogen 
degradation products. In this instance the early products also 
appeared to be more effective 'inhibitors than the late products 
(Kopec !! ~., 1966; Wilson!!!.!.., 1968). 
Kowalski ~ al. (1946b) worked with dogs infused with -strepto-
kinase-plasminogen to induce the formation of fibrinogen breakdown 
products. The appearance of early fibri~ogen breakdown products was 
found circulating in the blood. These products were correlated with 
profuse bleeding and pronounced prol~ngation of the bleeding time. 
The effect of early fibrinogen breakdown products was more pronounced 
than the effects of late-'breakdown products. Later work has shown 
the fibrinogen degradation products exhibit a maximum of anticoagulant 
activity at nine minutes (Nanninga, 1966). 
Latallo ~!!!.. (1964) clarified the role of early and late 
fibrinogen degradation products. These invest,igators demonstrated 
that the early breakdown products of fibri~ogen are plasmin susceptible 
and interfere with the action-of-thrombin, i.e. the enzymatic conversion 
of fibrinogen to fibrin monomer. The late fibri~ogen breakdown 
products interfered with the polymerization of the fibrin monomer and 
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are plasmin resistant. Recent investigation has indicated that the 
presence of fibrinogen degradation products may be responsible for 
defective fibrin clot formation. 
In 1962, B~g .!!..!!: using the electron' microscope, studied 
the effects of fibrinogen proteolysis products on the fibrin clot 
and demonstrated" defecti.ve fibrin polymerization. Low concentrations 
of fibrinogend.egr-adationpr-oducts produced" striking alterations in 
clot atZ'Ucture. Not only do pr-oteolytic products produce defective 
clots, but evidence also indlcates these products are actually 
incoZ'porated into the clot. In 1962, Latallo !!!!.. demonstrated 
that fibrin,ogen proteolysis products were, in fact, incorpor-ated 
into ., structurally abnomal clots. These workers suggested that 
proteolysis products inhibit polymerization' of the fibrin monomer by 
bonding with monoMr- units and in tbis way mask the sites essential 
for- nonnal polymerization. This t,heory was l.ater supported by 
Hirsch !!!!... {19(5) ,who indicated that large molecular weight 
products of fibrinogen proteolysis link with f !brin monomers and 
inhibit fibrin polymerization. This inhibition produced clots with 
abnwmal structural characteristics, including a" defect in the 
tensile strength of the fibrin clot. 
V CRYOFIBRINOGEN 
Shainoff and Page (1960) isolated a'product from the plasma of 
endotoxin tr-eated r-abbits that' corztesponded,on'the basis of its 
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peptide composition, to an intermediate product of the fibrinogen-
fibrin conversion. 'Since the product described precipitated in tbe 
cold at 4C)C, these workers suggested the term Ifcry'oprofibrin" ~ 
Later work (Shainoff and P,age, 1962; Sasaki ..!!.~., 1966) suggested 
thattbe liberation, of peptides'occurred during 'the fibrinogen 
exposure to ,thrombin. The .,resultant fibrinogen monaner polymerizes 
to form fibrin. In certain disease states the fibrinogen altered 
by the rele_e' of peptides, may combine with native fibrinogen to 
form a cold precipitable complex. Weerdt and Vreeker (1965) 
concluded that traces of thrombin formed ~ !!!.2..resulted in the 
formation of intermediate products of cryoprofibrin. Thrombin in 
trace quanti ti.es induces the formatIon of intermediate products, 
but not the formation of f !brin Itself. Therefore, . the presence of 
intermediate products results in the formation" of cold precipitable 
cry oprof!brin0 From the invest igat. ors , description, it seems 
possible that the cold precipitable 'protein described as cryoprofibrin 
is analagous to cryofibrinogen. 
Cryofihrinogen bas been demonstrated in the plasma of patients 
with carcinoma, leukemia, secondary polycythemia,,' and abdominal 
aneurysm in association with surgical procedures 0' This cold 
precipitable protein has" also been found, in small amounts, in 
samples from pregnant women, especially in the eighth month of 
pregnancy... When pregnancy was complicated by phlebitis, the amount 
of cryofibrinogen was increased. This protein was not evident in 
control s-amples from normal pe'l'Sons: (Glueck and Her'l'l'ftan, 1964) .. 
Lipinski !l.!!. (1957) indicated that the: cryoprecipitate 
described by previous workers may be soluble complexes formed in 
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the presence of excess. fibrinogen degradation products. These 
soluble complexes: may he precipitated by protamine sulfate or by 
cooling to 4°C. Lipinski and coworkers described these complexes 
as a result of .investigative studies using 1311 labeled fibrinogen. 
Samples of normal human blood were mixed with 131r fibrinogen and 
breakdown products of fibrinogen ~ The mixture was allowed to clot 
at 37°C for QQ minutes, and the resultant serum tested for radio-
activity. The amount of radioactivity in the serum was directly 
proportional to the amount of fIbrinogen breakdown products pNsent. 
Aliquots of the serum were cooled to 4°C and a cryoprecipitate 
occurred. From .. these experiments, Lipinski !!, £0 suggested tbat 
the cryoprecipi,tate termed by other workers astlcryofibrinogentt is 
a soluble complex formed by fibrinogen, fibrinogen degradation 
products, and intermedi.ates of .. the en~ymatic- conversion of fibrinogen 
to fibrin. 
The electrophoretic and immunoelectrophoretic behavior of 
cryofibrinogen has been found to' resemble fibrinogen (Korst and 
Kratcbvil, 1955). Recently, immunoelectrophoretic studies were done 
on a cryoprecipitate found in tbe plasma, but not the serum, of 
eight patients with cryofibrinogenemia (Zlo!neck and Landau, 196&) .. 
These studies demonstrated that the cryoprecipitate primarily 
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contained fibrin.ogen; h.anver, albumin and alpha, beta, and gamma 
. globulins were also -preaent. 
VI . INCREASED. FIBRINOLYSIS IN DISEASE 
As. early as: 19.1 ... , Gcodpasture repOl"'ted that blood specimens 
from patients witb atrophic hepatic ciwhosis exhibited clot 
diaeation w:ithin a few hours- at body temperature, while a clot of 
normal blood did notdigeat for days or weeks.. Goodpasture suggested 
that dissolution of the clot in the blood of ci:rrhotic patients is 
due to an enz.yme inhibited by nOl"'mal serum. Later, Ratnoff (19~9) 
confirmed thi .. finding and substantially-extended the study of this 
phenomenon. He noted that rapid plas.,ma clot lysis was a frequent 
accompaniment of Laennec's- cirrhos-is and waa sometimes observed in 
patients who experienced. hepatic -damage during the course of some 
other illness. However, rapid plasma clot lysis was not observed in 
either acute hepatitis or obs:tructivejaundice. unless. hepatic 
injury was~ associated. 
In recent years, several authors tFinkhinner .!!..!.!... t 1959; 
GroBsi !l.!!" 1901, 1962 j lewaan !l.!!., 1956, 1957; and Bergstrom 
!l !,!:' 19.6Q) have reported that a large proportion' of patients 
suffering from advanced hepatic ciIThosis exhibited rapid spontaneous 
lysis of whole hlood, siaortened euglobulin lysis times and other 
evidence of enhanced plaaminoaen-p lasmin activity. Other autbors 
have shown bepatic cirrhosis' is often accompanied by an ill-defined 
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coagulation disorder. Patients s.uffering from this anomaly may. 
when subjected to opel'at.ive stress., develop a severe hemorrhagic 
diathesis. This diathesis is often associated with pathological 
plasma proteolysis (Zucker !l.!!... 1957 i Ratnoff, 1954; Purcell aDd 
Phi llips, 196 3). 
Nocola and Soardi in 1958 associated increased fibrinolytic 
activity with all liver disease, particularly cirrhosis. Fletcher 
et 81. USe4) showed that patients suffering fl'om liver cirrhosis 
--
had an enhanced plasma fibrinolytic activity after the administration 
of ni.cotinic acid or after electroshock treatment. The increase in 
activity of cirrhotic patients was five times tbat of normal controls. 
Menon (1969) conducted a study onsubj ects randomly admitted 
to a medical ward with a variety of illnesses. Based on euglobulin 
lysis time, increased fibrinolytic activity was ascertained.. This 
investigator found tbat fibrinolytic activity was increased in 15 
per cent (two patientsl of the instances of coronaX"Y thrombosis, 10 
per cent of the instances of acquired valvular heart disease (10 
patients). and 18 per cent (.five patients) of congenital heart 
disease. In the instances of congenital and valvular heart disease. 
the li ver function tests were normal. Thus tit appears that 
increased fibrinolytic activity extends beyond liver involvement. 
Further suDstantiation of this involvement may be postulated 
from the wOJ'k of Todd. '~tS.9l who studied anatomic sites for fibrina-
lysis in tissues. Zones of fibrinolysis on a fibrin plate were 
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obsu-ved in all tlsaues except the live!'. Tha liver did. bowever. 
manifest fiDrinolytic activl.ty when ina diseased state. 'The zones 
of fibrinolysis were related . exclusively. to veins aD.d venules, 
except in the. lU:D1 . where these were related to pulmonary, arteries 
and arterioles. It would De expected thatiffiDrinolytic activity 
can De demonstrated. in tlle tissues a relationship between increased 
fibrinolyt.ic products and disease states ,.may he demon&trated. with 
the extenaionof tbe study of fibrinolytic prod.ucts. 
MATERIALS AND METHODS 
I SERA AND PLASMA 
Normal human serum and plasma were used to s'tandaroize the 
various test and experimental systems'. Pathologic serum and plasma 
wem studied for abnonnal f!bl'inogen degl'adation products. The 
patient sera used in this s,tOOy were collected fl'om hospitalized 
patients at the University Hospital and the Veteran's Administration 
Hospital. Specimen collection followed the routine procedure of 
each cUnical chemistry laboratory. The se:t"um was removed from the 
cells illlllediately after clotting. and stored at -20 C until 
immunological studies were performed. 
Samples of serum used as controls we:t"e collected from healthy 
persons previously screened as blood dono:t"S by the Blood Bank 
laboratory at the University Hospital. Specimens of blood were 
drawn according to tbe blood bankp:t"ocedure of this laboratory_ Tbe 
serum was i1llllediately removed f:t"Otn the cells and stored at -20 C. 
Samples of plasma were randomly collected from the outpatient 
laboratory of the University Hospital and from employees of tbe 
hospital. alood specimens were drawn in tubes containing sodium 
citrate. The plumawas X'emoved. pooled (8 to 10 samples per pool) 
and stored at -20 C until, needed. Pooled normal plasma was used as 
a fibrinogen control in immunological studies designed to identify 
fibrinogen anei/or fibrinogen products. 
32 
_II FIBlUHOG&H 
The fibrinogen used for this study· was dried buman fibrinogen 
procured from the AmerieanRed Cross (processed by Cutler 
Laboratories, Bel'keley, California}. FUty-five millip_ of the 
dried preparation _as Nconstituted in one milliliter of distilled 
water. Tbe resultant solution contained 10 mg/ml of clottahle 
protein. 
III ANTISERA 
The antisera used throughout these studies was obtained from 
HylaDCi Laboratories, Los Angeles. CallfOl'Dia. The polyvalent 
antisera were commercialpNparations obtained from animals (goat 
and rabbit) byperiuunized with poolednOl'Ul human sera. The 
antifibrinogen (.rabbit) or ant if ibrin (rabbit) antisera were 
prepared by hyperiDlDunization with washed -fibrin, processed from 
dilute solutions of purified human fibrinogen. 
IV- PLASMDlOGEN ACTIVATORS AND -INHIBITORS 
Proteolyses of fi»rinogen was studied by varying the 
concentration of plasminogen activators. The proteolytic agents 
used were a& follows: {l). Streptokinase-Streptoclomase varidase(R), 
a streptokinase pNparation obtained conmeJ:lciallyfrcm Lederle 
Laboratories, Pearl River, New York, and (2) Tbrombolysin(R), an 
acti vate4 human fibrinolysin obtained· cOI'Dmercially from Merck, 
Sharp, and Dobae. West PointtPennsy~vania. 
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The plasmin inhibitor used was Amicar (R}, a pl'eparation of 
e-aminocaproic acid Obtained commercially from Lederle Laboratories, 
Pearl River, Hew Yo:rk. 
"V, FllUUNOGEN ASSAY 
A modified,turDidimetric fibrinogen' assay was performed 
according to the me.tl.od of Hunter and Allensworth (1965). 
A. Sera 
-
Fresh plasma samples were. obtained frail two patients. Serum 
samplea from these patients previously demonstrated a positive 
test for fibrinogen and/or fibrinogen derivatives by immune-
diffusion. Plasma aamples from normal persons were used as. control 
samples. 
B. Reagents 
The precipitating reagent contained 14\ (w/v) ammonium sulfate 
3% (v/v) sodium. citrate and 1\ (w/v) sodium Chloride in distilled 
water. Five-hundredths milliliter of 17 per cent Zephiran was 
added to lQG ml of solution. The blank reagent contained 3% tw Iv) 
sodium citrate, 1% tv/v} sodium chloride and a.os, ml of Zepbiran 
in 100 ml. distilled water. 
C. Procedure 
Using Beckman cuvettes, 0.2 ml of patient plasma vas added to 
1.'" ml of blank reagent and inserted into a well of a Coleman Jr. 
apectrophotometer ,",Coleman Instruments Inc., Maywood, Illinois). 
At exactly three minutes. the apectrophotometer was adjusted to 100% 
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tl'anS1Dission at a wave length. of 400, mil. 
Using a matching cuvette to. 2 ml of plasma was added to 1.4 ml 
of precipitating Nagent. At exactly three minutes. the per cent 
transmission was recorded.. Each test was performed in duplicate. 
The fibrinogen level in milligrams per cent was determined from a 
previously prepared curve. 
VI CRJOFIBRINOGEN DETERMINATION 
The c~ofibrinogen method used was proposed by Kalbfleisch 
and Bird (1960). 
A. Sera 
-
Fresh plasma samples were obtained from two. patients. Serum 
samples from these patients. previously demonstrated a positive teat 
for fibrinogen and lor fibrinogen derivatives: byimmunodiffus;i.on. 
Plasma samples: from normal persons were used as control samples. 
ll. Procedure 
A fresh sample of plasma was refrigerated" for 48 hours' at 4 C. 
The cryoprecipitate was washed in cold s,aline and resuspended in 
saline to the original plasma volume. A fibrinogen assay was 
performed on tbe original plasma sample. and, the Nsuspended 
cryoprecipitate. 
VII EUGLOaULIN ,LYSIS TIME 
Euglobulin lya!$ time was 'performed according to the method 
proposed 1ly B.iggs and Mcfarlane (1963). 
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A. Plasma Samples 
Tbe following plasma samples were Obtained from the Clinical 
LaboratOX'iea: thNe samples with a prolonged prothrombin time and 
two samples- showing a positive serum test fOX' fibrin.ogen and/O'I.' 
fibrinogen derivatives by immunodiffusion. Plasma samples from 
normal pemona were obtained fl'om the outpatient department of the 
hospital and used fO%' controls:. 
Do. Regents 
The Nagents used for the test were 0.025 M calcium chloride. 
1% acetic acid t and 0.1\ bOl'ate a-olution. The horate solution was 
prepared hy dissolving 9; 8 sodium chloride and 1-8 sodium borate 
in one liter of distilled water. The solution was. adjus-ted to pH 
9:.Q. 
C. Procedure 
The blood w_ collected in s:odium citrate t kept on melting ice, 
and the test carried out within 2Q minutes after obtaining the 
specimen. Five-tenths. milliliter of the plasma was added to 
centrifuge tubes containing 9,. ml of distilled water. The pH was 
adjusted to 5.3 by addi~g 0..1 ml of 1% acetic acid. The tubes were 
allowed to stand at 4 C for 30 minutes. to permit the plasma 
euglo1)ulln fraction to pl'ecipitate. The tubes· were then centrifuged 
for five minutes. and the supernatant decanted. The euglobulin 
fraction was re&uspended by adding to eacb. tube Q.5 ml of the 
bOl'ate solut.ion. After the tubes were placed in a 37 C water bath, 
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0.5 ml of O.Q25 M calcium chloride was added and the clotting time 
recorded. After clotting, the tubes were inspected at intenals 




Samples of serum Obtained from normal blood donors screened 
by the University Hospltal Blood Bank Laboratories were used as 
controls. Samples of nonnal human plasma were obtained from the 
outpatient department of the University Hospital and were pooled 
(eight to ten samples per pool) and used as a plasma control. 
B. Patient Sera 
..... -_.-
A total of 198 sel'UJD samples from hospitalized patients were 
collected fr~ the Clinical Chemistry Laboratories of the 
University Hospital and the Veteran's Administration. Hospital. 
The specimens were frozen at -20 C until immunological studies were 
performed. 
C. Procedure 
Patient sera were screened immunologically on immunodiffusion 
plates commercially prepared by My land Laboratories (Los Angeles, 
Californial. ren microliters of the test samples. were loaded in 
the wells on the immunodiffusion plates. Each sample was run in 
triplicate. A control sample of normal. human plasma was used on 
each plate. Ten microliters of fibrinogen vas placed in the aentel' 
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well. After loading It the plates were allowed to. incubate for 48 
hoUl'S at room tempe.l'at.uI'e in a moist chamber. The results were 
read and recorded at 24. and 72 hours GO Since there was. no 
significant difference in these readings, only the 24-bour reading 
was recorded. The presence of fibrinogen and/or fibrinogen 
degrad.ation. products was determined .. by the presence of a precipitin 
band (0 (see Figure 7) 
IX IMMUNO£LECTROPHORESIS ON CELLULOSE ACETATE 
A. Fibrinolytic Agent 
Tbl:'ee di.lutions of commercial plasmin were prepared in tbe 
following manner: (1) 100 mg of plasmin (10,000 units) was 
reconstituted in 0.1 ml distilled water; '-2) 10 mg of plasmin 
(1,000 unit.s). W.as reconstituted in 0.1 ml of distilled water; 
and (.3) 1.0 ag of plasmin (.10·0 units) was reconstituted in 0",1 ml 
of distilled water. 
B. Ruffer 
The buffer solution. 'pH 8.6, ionic strength.. 00075) was 
prepared »y dissolving 2 0 76 & of 5,5-diethylbarbituric acid and 
15.40 g sodium S,S-diethylbarbituric acid in distilled water to 
make one liter. 
e. Protein Stain 
Ponceau-S fixative dye solution was used as the protein stain. 
The dye solution contained 0.2\ (w/v) Ponceau-S stain, 300% (w/v) 
trichloroaceti.c acid, and 3.0% (w/v) sulfosalicylic acid in water. 
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Fig. 7. Immunodiffusion plate. The double diffu-
sion test was carried" out in buffered agar. Anti-
fibrinogen was applied" in" the center. Applied in 
the five different spots were: normal human plasma 
(starting from top, counterclockwise) and four 
serum samples from hospitalized patients. The 
precipitin bands represents th~ presence of fibrin-
ogen breakdown products. 
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D. Procedure 
Cross-reactivity of plasmin with respect to commercial 
antifihrin,ogen was studied using cellulose acetate strips and 
Microzone equipment (.Beckman Instruments. Fullerton t California) in 
accordance with .. preswiDed pl"Otocol (RyeX'S, 1966). The power 
supply used was a .Spinco Duostat: (Beckman Instl"UDlents., Fullerton, 
California). Normal human plasma was used as a control. 
Cellulose acetate membranes were presaturated with buffer and 
placed in at) embosser that embossed tbe membrane with·two wells for 
the 88q)le and three troughs for the antisera. The membrane was 
then mounted on the Microzone (Rl electI'ophol"8tic cell bridge and 
0.3 ",1 of plasmin dilutlona were applied. Electrophoresis was 
performed at 150 volts for SO minutes at room temperature. The 
membrane.was then removed from the bridge, antifibrinogen (2Q lJll 
was applied, to each of the three troughs. followed by immersion in 
light mineral 01.1 and incubation for 66 to 72 boul'S at room 
temperature. After incubation. the membrane was rinsed two times 
in petroleum ether and four times in normal saline • stained in the 
fixative dye solutionfatt seven minutes. rinsed three more times in 
st aqueous acetic acid anddJ'ied in a drying frame before a hot-air 
dryer for 20 minutes. 
X IMMUNOELECTROPHORESIS. IN AGAR GEL 
Immunoelectrophoresis was performed on camnercial illDuno-
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electrophoretic equipment (Gelman Inst.ruments~ Ann Arbor, Michl,anl. 
The pOlffer supply used was a Spinco Duostat (.Beckman Instruments, 
Fullerton, Califomial. The method used was the microtecbnique of 
Scheide"er {lQSS} as. modified by Hirschfield (1960). 
A. !e!:. auf fer 
The a,ar auffer .as prepared by disaolvio, 1.&6 , :barbituric 
acid, lCL.$l I sodium bar»-iturate, and 1.5.4 , calcium lactate in one 
liter of distilled water. The al>ove .,olution was adjusted to a 
pH of 8.6. 
B. TanJc B.uffer 
----
The tank buffer was prepared by dissolving 1.38 , barbituric 
acid, 8.7 g sodium harbiturate, and 0.399 g of calcium lactate in 
ene liter of distilled water and adjusted to pH 8.i. 
c. Agar 
The two per cent. agar medium was. prepared Dy dissolvin, 20 g 
of conmercially prepared Ion Alar (Difco Laboratories, Detroit, 
Michi,an) in one liter of distilled water. The agar s.olution was 
slowly brought to a boil and. allowed to boil until the agar was 
canpletely dissolved. The medium was then allowed to s,olidify in 
SO ml aliquots. 
D. Protein Stain 
The dye used for staining the slides, was. prepared by dissolving 
one gram .acb of thiazine red R, amidoschwarz 10. B, light green SF, 
mercuric chloride, and 2Q g of acetic acid in one liter of distilled 
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water (.CrONle •. lUll. 
E. Procedure 
Three horizontal fl"arDes were: used, each holding six microscope 
s.lides. previously cleaned wi tIl. alcohol and coated wi tl- agar by 
inmersion in a llotling a.2\ 'w/vl i.on agar. 
Fifty mi.llillteN· of tne· previously prepared.ag .. was melted 
by hoiling and then allowed to cool to approximately 56 C. While 
still warm, the agar auffer mixture was applied to each series: of 
six slides in the hO%'izontal frames:. {Approximately 20 ml of agar 
••. needed for each; frame.) After the agar was s.olidified. eaen 
slide was, punched with. a die des:igned to cut two wells for the 
&ample and a center trench between the wells for the antiserum. 
The horizontal frame. were placed in the electrophoresis: cell 
previously filled with buffer. Cellulose acetate wicks. 
presaturated in. buffer'. were used to connect the sUdes· with the 
buffer. A constantcuXTent of 35 ma was:· applied for about 20 to 3tl 
minutes.. The frames were. removed from the cell and the agar was 
aspirated fran the wella. In each case. 5 pl. of the control 8-ample 
marked with Bromphenol &lue {Hartman. Leddon Company, Philadelphia. 
Pennsylvania), was: loaded in the top well and the bottom well was 
filled with 5 111 of the sample to be tes."ted; the frames were 
returned to the cell and the current '35 mal applied for 
approximately one and one ... half to two hours;. 
The cell was again. opened and the agar was aspirated from the 
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center tl'encl\., tie trench was then filled wi:t1l 100. 111 of 
ant ifibrin osen • The slides. were allowed to incubate at room 
temperature in a moist diffuaion chamber for 24 hours:. After 
incubation, the al1dea were washed intbNe 24-hour rinses of 
normal saline and one 24-AoUl" rinse of distilled water. Tne slides 
were dried in a hot-air dxyer and stained for approximately 30 
minutes. The excess, s:tain was removed by rinsing hrief 1,. several 
times in cold tap water. A final rinse in 5% aqueous acetic acid 
was· used. for differentiation of the stain. After drying, the 
stained slidea were laheled and the results. recorded. 
Xl GEL FILTRATION 
A. Preparation. 2!. DeEmation Products 
Dried hwaan flbrinOien was reconstituted to 55 mg/ml in 
distilled. water &ivinS a final concentration of 10 mg/m1 of 
clottable protein. To 5 ml of tne reconstituted fibrinogen was 
added 0.15 ml of plasmiD, giving a final dilution of 300 units of 
plasmin per milliliter of fibrinogen. Proteolysis' was ·allc.ed to 
proceed far 48 hoUN. 
B. Preparat ion. 2!!!!!. Column 
G-75 and G-2QO. Sepbadex (R} (Phal"lDacia Fine Chemicals, 
Incorporated, Piscat_ay t New Jersey). were -allowed to swell in 
demineralized wa'ter for three days with periodic. water chanaes 
dl.Jlling this ti_ and:. the- fine materials raaoved by- decantation. 
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The water w_ then Nplaced wi'th,O.85\ sodi_ chJ.oride. 
The Sepbalex vas allONeci to equilibrate with.the saline 
solution befON })ainl packed into a column 2 .. S em in cliUleter by 
45 an in height, or a column 2 .. 5 em in diameter by 100 em in helpt. 
Coltal packing was accomplisbed by pouring a sllU'TY of Sephadex and 
saline into the column. The outlet of the column was adjusted to 
avoid excessive packiDl' of tbe lel beads. The slurry was 
cClOtinually NplaceG .. pacJdng proceeded until the packed gel bed 
was the desired height. The column was fitted with upward. flow 
adaptOl'S and. cODneC'ted to a saline l'eservoir. Saline was allowed 
to l'Un thl'ouah· the column overnight. 
c. PJ:tocedU1'e 
Five milliliters of the sample were .appliedt.o the column 
usin, a tb........,ay valve andsyTlnge and-the pressure was adjusted 
to allow a flow rate of 9· ml/br through . the col\RD. A total of 
three fractiCDa. containiDa tbJ;tee·1Rillilit.ers of effluent were 
collected each hoUl' at 2.QmiDute intervills with an '''ISCO(Rl automatic 
fraction collector (.Ill8tJ:tu11entation Specialties Company, 
IncOl'porated, Lincoln, Hebl'aska). The tubes were analyzed for 
protein content uaiD& a BeciJDan DU . ultravi,olet llghtspecU'o-
photometep (.Beclaaan Inatrw.nts, Fullerton t California), with a 
wavelength setting of 280- mll. The aptlcal density was graphed as 
the OI'di.nate aDd the volume of the effluent was plotted on the 
abaci •• a. The effluent fran -the tubes defined within tbe absorbance 
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peaks iD the above plot were pooled and concentrated ten-fold 
using LypbOgell,'Rl a polyacrylamide gel acting as a dehydrating 
aaent (.Gelman Inatl'UJDen'ts. Ann Arbor, Michigan). 
EXPERIMENTAL RESULTS 
1. CROSS-REACTIVITY OF PLASMIN 
Throughout these studies plasmin was consistently used to 
effect the proteolysis of fibrinogen. In order to correctly 
identify the breakdown products resulting from fibroinogen 
proteolysis, the necessity of ruling out cross-reactivity between 
plasmin. and antiflbI'inogen<became evident. 
Agar gel immunoelectrophoresis was performed on the following 
dilutions of plasmin and expressed in MSD unitsl lO,OOOunits/ml, 
1,000 unitslml, and 100 units/ml. Table 2 indicates that no cross-
reaction occurred using 100 unitslml and 1,000 unitslml of plasmin. 
However, when 10,000 units/ml of plasmin were tested with anti-
fibrinogen, a light pl'8cipitin band occurred in the alpha area of 
the electrophoretic pattern extending into theprealbumln region. 
To eliminate the further possibllity of cross-reactivity of 
plasmin wi.th the agar gel t cellulose acetate immunoelectrophoresis 
was performed on the above dilutions of plasmin, using antifibrinogen 
as the antisera and normal buman plasma as a fibrinosen control. A 
light band, iOOlcatiDg cross-reactivity, was again· seen with this 
concentrati.OD of plasmin (10 ,000 units), but was notevldent at 
lower concentrations 'see Table 2). Therefore, dilutions of plasmin 
were maintained below 300 unitalml in subsequent studies to avoid 
observable Dcmapecificprecipitin bands. 
Table 2. Immunoelectrophoresis of Plasmin 
UNITS OF AGAR CELLULOSE 
PLASr·1IN GEL ACETATE 
100 NEGATIVE NEGATIVE 
1,000 NEGATIVE NEGATIVE 






IaunodiffusiOll was used to. screen patient sera for the 
presen.ce of fibrinogen and/or'derivatives of fibrinogen'.' A total 
of 196 samples of serum frOlllhospi,talized patients was- collected 
from the Clinical-eheads.try· LabOl'atOl'ies of the· University' Haspi tal 
and the Veterau~s Admin.i:atration,Hospital. 'Altb.ough most of this 
population had a history of abnormal liver function.. a widespread 
spectrum of diseasewa repNSented •. ,I.mmunodiffusion was. performed 
in triplicate with ,all serum samp les. Fl'om' the 196 serum s .. ples 
sCNened, ten aample& (approximately 5\1 gave visiDle immunological 
Nactiona with antlfibrinogeD. lndicating" the presence of fibrinogen 
and/or braakdorm, products of fi»rinogen. Immunocli.ffusion was also 
performed on control sera collected from So. persons' previously 
screened for' blood. donation- by • the Universi.ty Rospit.al B.lood Bank 
Laboratory. Neither fibrinogen J1OI' fibrinogen breakdOlll'l products 
were demonstrated. in the sera of the controls.. Using 1) iagnostic 
Flasma (Hyland Laboratories, Los AngelestCalifornia) as a 
fibrinogen ref8l'e1lce. studies indicated that fibrinogen in amounts 
exceeding J.Q JOg was demonstrable by immunodiffusion. 
III IMMUHOELECTROPHORESIS 
From the various teat systems employed, it appeared that 
immunoelectrophoretic technique" was most satisfactory for 
identifying and Cbaracterizfng the procluctsresulting from the 
proteolysis of human fibrinogen. Preliminary studies were made 
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using two different ,agents- to induce fihrinolysis. These studi.es 
were conducted. to detemine which agent would be best suited for 
study of fibrinogen. breakdosm··products. These .agents were 
Thrombolyain '-cOIDIIle.rcial plasmin)' and Streptokinase '.a plasminogen 
activator 1. 
When" immunoelectroph.oNs;is was performed on normal liwnan 
plasma after beiDa suDjecteci iothe 'proteolytic activity of plasmin, 
two distinct bands were observed in the alpha-beta zone (see Figure 8). 
Both hands. differed from the nOZ'lllal immunoelectrophoretic position 
of fibrinolen. For purpoaa. of this discussion.. the hand migrating 
neareat to the origin was labeled Band A, while the band with the 
faster mipation rate 'Was labeled Band B.. The following experiments 
'WeX'CJ based on the assumption,that tile_ products represent the D 
and E fractions respectively, as. originally reported by Mussenweig 
and co-workers, {19601. 
Streptokinase •. as used in preliminary experiments. as a 
plaaminogen activator. This activator was added to samples of 
poo~d normal human plasma, and proteolysis was allowed to proceed 
for perioda of ti_ from Z8Z:-0 to three hours. The timing was 
synchronized to allOill all samples to be innoculated on the agar 
sel aimultaneoualy. After loacllng, a constant current was 
i-.diately applied to the cell. Tbe results; of this, expez:-iment 
are &i ven in FilUl'e 9,. 
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Fig. 0.. A diagramatic representation of the immtlnoelectroph-oretic 


















Fig. 9. Streptokinase activation of normal human 
plasma (NHP) at varying periods of time. 
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aug.eated in .a~ case.})!, tile presence of two precipitin D,anc.\S. 
Band A. nearest tbe _11. Nmained in a s.table position regardless: 
of timing. HoIrrevel'. Band B., migrating fUX'thest from the: well, 
varied in mObility depending upon the time. allowed for proteolysis; 
to .. proceed. Streptokinase.as added to normal human plas.ma 
iJ'lll'D8d.lately ])efore loading. Figure 9 illustrates tnat proteolysis 
. ..,. baveoccw:-red intttantaneous;,ly '-note time zerol, or that the 
pluminogen may have :Men activated sometime during the electro-
phoretic procedure. 
Tae above treatment of normal human plasma was repeated 
substituting lO~ ~/ml of plasmin in lieu of streptOkinase. In 
Figure 10 it can be seen that the action of plasmin differs from 
atreptokinaae. Although the same two products; are evident, the 
mobility of 'the E components differ. Comparing Figm'e 9 with 
Figure lo,it appeax's that proteolyais of f.£brin,ogen occW!'& at a 
alower rate when plasmin is used. Repeated experiments supported 
this finding and als~ indicated that plasmin gave more reliable 
and reproducilale reaults·. Fozt these reasons, plasmin was used in 
subsequent experiments. 
I V THERMAL PROPERTIES OF FIBRINOL1TIC PRODUCTS 
Usina a.imple radial diffusion technique. B.eller and Malei '1961) 
c:1emonatratec:1 two products resulting from the degradation of 
fibrinogen lay plasmin and ident.ifiec:1 these products as the D and E 
fractions originally reported It.ly Nussenweig (1960). The above 
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Fig. 10. Serial digestion of fibrinogen in 
normal human plasma (NHP) by plasmin. 
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!Dvestigators alao reported tbat after beati~g the, filiz'inolytic 
products, the pl'oduct deS:ignated by these workers: as the D fZ'acticn, 
could no longer be demonstZ'ated. The thermolabile propeZ'ties of 
fraction D andtfte thermoatabile properties' of ~action E were 
later substantiated by Kowalski '1968). 
Plasmin '-100. lA/mll was added to -two samples of pooled normal 
lU.uoan plasma. B.otL samples: were allowed to incubate at x-oom 
temperature for one D.Ot.lX'. Following incubation, one of the samples 
(sample 2) was heated in a 56 C water b.ath for 30 minutes. Sample 1 
was used as. a control. Immunoelectrophoresis: was:perfonned on both. 
samples 'see Fi.gure ll}. The control sample was placed in tbe 
upper well, whereas'·"'tb.e beated sample was; placed in the lower well. 
Two products were demonatrated in the upper well and only one 
procluct was demonstrated in the lower well, &uggesting that the 
heavier hand t Band At misrat~g nearer the origin, represents tbe 
proteolysis procluct previously described as the D fraction. 
V INHIBITION OF PROtEOLYTIC ACTl VIn 
Allc.j aersig et ale (1959a) "ported that the proteolytic action 
--
of plasmin is inbii.ited. by e-amino caproic acid. bowever, attempts 
in this study to inhibit the proteolytic acti,on of plasmin in normal 
human plasma were UllSuccesaful. Thus, an experiment was designed to 
determtnetbe threshold of c-amino caproic acid plasmin inhibitory 
activity. purified human fibrinogen was reconstituted to SS mg/ml 
in distilled water living a fil1al concentration. of 10 mg/ml of 
30 MIN PLASMIN DIGESTION 
60 MIN PLASMIN DIGESTION 
PNHP 
ANTIFIBRINOGEN 
PNHP (56. C) 
PNHP 
ANT IF IBRINOGEN 
PNHP (56 C) 
Fig. 11. Plasmin digested normal human plasmin 




clottable protein. £-amino caproic acid was added to each of seven 
tubes containing one milliliter of fibri~ogen,. giving a final 
concentration of 50 mg/ml of the fibrinogen solution. Vary~ng 
dilutions of plasmin, as indicated in Table 3, were then respectively 
added to each tube. Control tubes contain~ng fibri~ogen, but not 
£-amino caproic acid, were prepared to indicate the proteolytic 
action of plasmin at each respective dilution. After the tubes were 
incubated at room temperature for one hour, immunoelectrophoresis was 
performed on all samples us~ng antifibri~ogen as the antisera. When 
two bands representing fibrinogen breakdown products were observed, 
the sample was described as not inhibited. It may be noted from 
Table 3 that proteolysis did occur in each of the control samples. 
However, when less than 40 units of plasmin was used, the proteolytic 
action was inhibited by the €-amino caproic acid. 
VI GEL FILTRATION 
Normal human plasma treated with plasmin for 48 hours was 
applied to a column of G-75 Sephade~ gel and a column of G-200 
Sephadex gel. Fractions were collected and analyzed for protein 
content. The peaks represent~ng the distribution of protein were 
ascertained by plott~ngoptical .. density on ~ graph (see ~igure 12). 
The tubes containing the absorbance peaks were pooled and concentrated 
and immunoelectrophoresis was performed on the resultant concentrates. 
It .was observed by inspection of the immunoelectrophoresis slides 
that partial separation had been accomplished. Samples from the 
56 
Table 3. Inhibition of the proteolyte Activity 
of Plasmin on Fibrinogen by ~Amino Caproic Acid 
(EACA) 
TUBE FIBRIN- EACA PLASMIli PROTE-' 
OGEN OLYSIS* (mg/ml) (mg/ml) (in units) 
Control 1 10 -- 100 HI 
Sample 1 10 SO 100 NI 
Control 2 10 
--
80 NI 
Sample 2 10 SO 80 NI 
Control 3 10 
--
60 NI 
Sample 3 10 SO 60 NI 
Control 4 10 -- SO NI 
Sample 4 10 50 SO NI 
Control 5 10 -- 40 NI 
Sample 5 10 SO 40 NI 
Control 6 10 -- 30 NI 
Sample 6 10 50 30 Inhibited 
Control 7 10 -- 20 NI 
Sample 7 10 50 20 Inhibited 



















o " 500 100'0" 15'00 
Elution Volume (rol) 
Fig. '12. Pattern obtained after filtration of fibrinogen degradation 
produ'ets through Sephadex G 200. 
~ 
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absorbance peak first eluted from the column contained both the D 
and the E fractions while samples from the second peak contained 
only the E fraction. 
VII ASSAY FOR FIBRINOGEN AND CRYOFIBRINOGEN 
A modified ,turbidimetric fibri~ogen assay (Hunter and 
Allensworth, 1965) was utilized'to determine the fibri~ogen levels 
on plasma samples. Inasmuch'as fresh plasma was required for the 
analysis, two persons with. nopmal plasma fibrinolytic activity and 
two patients with increased plasma fibrinolysis were selected 
because of availability at the time of testi.ng. Fibrinogenand/ or 
fibrinogen breakdown products had been demonstrated immuno~ogically 
from serum samples previously obtained from these patients. The 
normal range of fibrinogen for this method is 180 to 415 mg/IOO mI. 
Although the patient values were considerably ~igher than those of 
the control, only one of the fo~ patients (see Table 4) may be 
i 
considered as having a s~ightly increased fibri~ogen level. Samples 
of plasma from the same. group:.of patients weve refrIgerated at 4 C 
and observed for cryofibrinogen (Kalbfleisch and Bird, 1960). After 
48 hours, no cvyoprecipitate was observed, in any of the samples. 
VIII EUGLOBULIN-LYSIS TIME 
Increased fibrinolytic activity has been determined by the 
euglobulin lysis time in patients with a history of abnormal liver 
function tests and coagulation disorders (B.iggs and McFarlane, 1963). 
Table 4. Assay for Fibrinogen and Cryofibrinogen, 
!I 
SAMPLE FIBRINOGEN (MG%) CRYOPRECIPITATE !: 
I 
CONTROL A 270 t!ONE , I 
1 
CONTROL B 180 NONE , ! 
f 
, 
PATIENT A 450 J~ONE I 




The' followi,ng fresh plasma samples were studied: five samples with 
coagulation test values in' the ",normal r~n~e, three samples with 
prolonged prothrombin times', '.and.two samples showi,ngthe presence of 
fibrinogen and/or fibri~osen'derivativesby immunodiffusion. The 
clotting time was recorded ',as: well as the time required for the 
lysis of the clot. Clot' lysis' times lO,nger than two hours were 
considered to be in the normal r~nge. Only one plasma sample (see 
Table' 5) showed increased'fibrinolytic activity as demonstrated by 
the Euglobulin lysis test'~ .,. A.' positive test for fibrin:ogen and/or 
fibrinogen derivatives by immunodiffusion was previously demonstrated 
in the serum obtained from this patient. 
IX' 'PATIENT DATA 
As previously stated", 196 samples of sera were collected ,from 
patients hospitalized at'the"University Hospital and the Veteran's 
Administration Hospital." Thirty samples of sera were collected from 
persons previously screened as blood donors by the University Hospital 
Blood Bank Laboratory and used as normal controls. All' samples were 
screened by immunodiffusion'for the-presence of fibrinogen and/or 
fibrinogen breakdown products. These products were not demonstrated 
immunologically in anyof'the control sera; however, in ten of the 
sera obtained from hospit,alized patients fibrin:ogen and/or fibrinogen 
products were demonstrated~ 'Immunoelectrophoresis was performed on 
each of these ten samples,' usi,ng normal human plasma degradated with 
plasmin (100 units/ml) as a'control and antifibriIl:ogen as 'the 
Table 5. Euglobulin Lysis 
SERA SAf,'PLE 
... . ....... " ... 
CONTROL A 
CONTROL B 




PROLONGED PATIENT 1 
PROTHROMBIN PATIENT 2 
TIME PATIENT 3 
POSITIVE PATIENT A 
" IMMUNODIFFUSION ... PATlENT .. B··.. . 
--
CLOTTING 
.... , .TIME 











. . ... 2 .. MIN· .. ··· 
LYSIS 
" 
. . ...... TIME 
2 HR., 30 MIN. 
2 HR., 50 MIN. --
2 HR., 40 MIN. 
2 HR., 10 MIN. 
2 HR., 10 MIN. 
2 HR. ,30 MIN •. 
2 HR., 40 MIN. 
2 HR., 5 MIN. 
2HRt, 5 MIN. 




antisera. One band, corresponding to the hand desC1'iDed as the D 
fraction. was demonstrated in e,iglit of the· ten samples:, and in the 
other two sel'Umsamplea bands representing the D and E fractions 
were demonstrated .. 
Medical bis.tories of these patients were: oJ)tained and a diagnostic 
claaaifi.cation was made. Tile di:agnosis of the patients' illness at 
the ti_ of this study was, performed could be olassif ied in to three 
categories: (.1); hepatic disease, (.2} kidney disease, and (.3) intra-
vaacular thrombosis,. A s.uhclasaif lcation of eac~ of these three 
categories is: presented in Figure 13. Eight of the ten patients 
were being treated for liver aiImenta. These included viral 
hepatitis, cirrhosis. of the liver,cbronic passive conges.tion. and 
biliary disease. The kidney ailments afflicting five patients 
included kidney -infection, myeloma nephrosis:, kidney infarction, and 
nephroscleroai,s. Six patients had intravascular thrombosis, which 
included one patient with an abruptio placentae .. 
In s,ome ins, taJI·ces,. evidence of more than one dis:e·ase process 
wi thin a single patient was found. i.e., three patients presented 
with a bistory of all three disease entities .• while one patient had 
kidney disease accompanied by intravascular thromboais and one patient 
had. both. hepatic and kidney disease. A diagranmatic pres.entation of 
the overlap of diseasea. is given in Figure 14.. The arabic numerals 
indicate the number of patients, in each categ~. Itmay De noted 
that there were no case a of kidney problems without the added 
eanplication of either liver disease or intravascular thrombosis:. 
LIVER (8) 
VIRAL HEPATITIS (1) 
CIRRHOSIS (2) 
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CHRONIC PASSIVE CONJESTION (3) 
BILIARY DISEASE (2) 
KIDHEY (5) 
I IlTHAVASCU LAR 
THROr.1BOS I S 
(6) 




ABRUPTIO PLACENTAE (1) 
Fig. 13. A classification of disease states seen 







Fig. 14. A diagrammatic repr.esen-tatci.an of ·the oVer'l.ap of' phys'iei.-egic sites 
involved in' the diseasep'iatl:S'of' pati:ents· wi'th t'ibrln'O"g'e11 brea:1atown products 
in<the- serUm. • .J: 
DISCUSSION 
Immunological methods have been employed to demonstrate and 
identify the proteolysis products resul ti.ng from the degradation of 
human fibrinogen by plasmin~ The proteolytic breakdown products of 
fibrinogen studied include' products occurri.ng spontaneously and 
products induced by treatment with streptokinase ,and plasmin. The 
fibrinogen degradation products studied were derive~ from: (1) 
normal human plasma treated with the fibrinolytic .agent plasmin, (2) 
normal human plasma treated with streptokinase, -an activator that 
converts the proenzyme plasminogen to plasmin, and (3) spontaneous 
products occurring in the serum of ten hospitalized patients. 
Direct observation of the'digestion process was facilitated when 
immunoelectrophoresis was performed on normal human plasma subjected 
to varying periods of exposure to the proteolytic .agent, plasmin. At 
time zero, the fibrinogen molecule had already begun to split, 
indicating the occurrence of rapid proteolysis that may have occurred 
during the electrophoretic procedure. At fifteen minutes Band A 
representing the D fraction'wasobserved. This band remained stable 
and did not differ in immunoelectrophoretic position regardless of 
the time allowed for proteolysis to proceed. The second band, Band B, 
varied in immunoelectrophoretic position depending on the length of 
exposure to the proteolytic agent. From these results it appeared 
that this band may represent an intermediate product containing the 
E fragment rather than a plasmin resistant product. Furthermore, it 
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appeared" that this intermediate ,product is still susceptible to the 
action'of plasmin. However,"exhaustive:proteolysis (48 hours) 
produces an E fragment resistant to'further action by plasmin. This 
postulate is further substantiated by the increased electrophoretic 
mobility after prolonged"exposure~of,this intermediate to the 
proteolytic enzyme. The appearance'of a spur on the anodal end of 
the precipitin band of the E fragment" with extended digestion suggests 
that polypeptides are being continually split from the intermediate 
product containing the E fragment. With exhaustive proteolysis of 48 
nours, the spur disappears and the E fr,agment, resistant to plasmin, 
now appears in the prealbumin electrophoretic region rather than the 
original alpha-beta position. 
The ~oncordant opinion as to the exact rate and mechanism 
involved in the formation of" the D and E fractions from the parent 
fibrinogen molecule has not" been-established. The recent work of 
Kowalski (1968) has indicated' that dur~ng plasmin proteolysis of 
fibrinogen',' fractions D and' E' are formed at the same rate (see 
Figure 6). However, the" study' presented herein indicates that 
fragment D is formed more" rapidly and" remains stable, while E is 
formed ata slower rate. Kowalski formulated his composite hypothesis 
of this'mechanism (see Figure' 6)'by' compiling several discreet 
experimental studies. In the present study, a sequential degradation 
of the parent molecule was serially observed. This digestion yielded 
a rapid formation of the D fragment and a sequential alteration of 
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theE'moiety. This produced'a'~igratory band o~igiriat~ng in the 
locus of the D fragment and' p~ogressi,ng across the electrophoretic 
field to the prealbumin regionat'the completion of the ~igestion. 
A diagrammatic representation'of'this process is, given in Figure 15. 
This mechanism is supported'bythe earlier work'of Fisher !!!!., 
(1967)~ Using zone electrophoresis in polyacrylamide, gel these 
investigators indicated that'the electrophoretic mobility of the E 
moiety continues to change'until there is a clear separation of both 
precipitin lines. Complete'separation appears to require a digestion 
period of approximately 24 hours, This work substantiates the postulate 
that the bands seen in Figure 10 (note 48 hour) represent the final 
products resulting from the 'proteolysis of fibriIl:ogen'byplasmin, and 
indicates that the rapid-formation of the D fragment may be a more 
reliable observation of plasmin'digestion. 
Recent studies performed by Beller and Maki (1967) using radial 
diffusion confirm an earlier'proposal, i.e., when fragment D is 
sUbjected to temperc;ltures' of' 56' C or ~ighe:r;', the fr,agment' precipitates, 
altering its molecular structure~' To substantiate the identification 
of Band A, previously described in this work as the D fragment, the 
thermolabile properties were studied by heat~ng plasma and plasmin 
treated plasma to 56 C for 15 minutes. Immunoelectrophoresis of this 
sample demonstrated that' the product migrati.ng near the well was no 
longer visible, thus establishing the identification of Band A as 
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Fig. 15. Model of fibrinogen digestion by plasmin. Plasmin digestion appears 
to give immediate rise to two D. fragments and a. sequential degradation to two 





Gel filtration chromat.ography usi,ng Sephadex was· employed to 
separate and further identify the l~rger fr.agments formed during the 
proteolysis of fibrinogen,-i~e.~-f~agment D (molecular weight 80,000) 
and fr,agment- E (molecular- we.ight- 30;000). Followi,ng- fractionation on 
the column, immunoelectrophoresis was performed on the-two absorbance 
peaks. Both Band A and Band B'wereobserved in elution samples 
contained in the first absorbance peak. The D fragment appeared to 
be present in a greater concentration than the E fragment. Only 
Band B was demonstrated in the elution samples contained in the 
second absorbance peak, indicating that partial separation had been 
accomplished. The larger molecular weIght fragments would be 
expected to be eluted from the column before the smaller molecular 
weight fragments. Since partial separation was obtained and Band B 
appeared as the exclusive'component in the second peak, Band B 
most probably represents the Ef~agment. 
When electrophoresis'was performed on normal human plasma 
following the addition of-streptokinase (refer to Figure 9) a 
different pattern was observed~ Two precipitin bands were'visible, 
one appearing in the beta-r,egion.,just above theor,igin, and the 
secondanerging initially'from-the anodal end of the first'into the 
alpha region. The presence of· two precipitin bands at time zero, 
instead of one, would indicate'that the action of streptokinase is 
faster than the action of'plasmin~ However, at 30 minutes the band 
representing the E moiety'demonstratesa slower electrophoretic 
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mobility and greater identity with f~agment D. This spur could 
possibly result from recontugation of the E moiety into an intermediate 
product, a "reversal" effect. Further d.egradation of the D fragment 
would not be a plausible· explanation for the spur, in that the plasmin 
resistant end product of theE fraction is not seen. The reversal 
effect exhibited by streptokinase has not been explained from the data 
presented herein. However,· the occurrence of this effect has been 
substantiated by Hunter and' Allensworth (1966). These workers 
demonstrated by serial fibrinogen assays a biphasic effect on fibrino-
genolysis result~ng from the· addition· of streptokinase, i.e., after 
one hour fibrinogen levels' were approximately 25 to 33% of the 
starting material, whereas withprol~nged streptokinase treatment 
fibrinogen levels returned· to approximately 75% of the o~iginal assay. 
(see Figures 16 and 17) This'effect was not seen when fibrinogenolysis 
was initiated using commercial. plasmin in excess. A possible 
explanation for the differences observed in the type of reactivity of 
plasmin and streptokinase may relate to the qualitative and 
quantitative kinetics of the enzyme' systems. Mathematical and 
experimental studies by Li~iger and. Rll:egs.e.gger (1967) showed that 
when streptokinase (an activator) enzymatically activates plasminogen 
generating the active enzyme plasmin, an antiactivator inhibits 
streptokinase and plasmin' is' inhibited by reacting stoichiometrically 
with antiplasmin. It appears, however, the excessive extrinsic 
plasmin will completely hydrolyze fibri~ogen and/or fibrin to stable 
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D and E end'products. 
Serum samples from 196" patients were collected at random without 
prior knowle,dge of the admitti,ng- diagnosis. Immunodiffusion was 
employed to screen these sera for the presence of fibri~ogen and/or 
breakdown products of fibrin,ogen. Since fibrin,ogen is completely 
converted during the clotting'process, (Rodman, 1968) the presence 
of fibrinogen and/or products of,fibri~ogen in the serum in traceable 
amounts were considered abnormaL, indicat i,ng a disease state. 
Fibrinogen and/or breakdown-products of fibri~ogen were found in the 
serum of ten patients,or approximately 5% of the 196'serumsamples. 
Immunoelectrophoresis was'employed to further characterize the 
products demonstrated by immunodiffusion. A band appeari.ng in the 
same immunoelectrophoretic'position as the D fraction was demonstrated 
in eight of the ten sera,-whilebandsoccupy~ng the immunoelectrophoretic 
positions previously observed for both the D and E fractions were 
demonstrated in the remaini.ng two sera. Since the filteri,ng threshold 
of the glomerulus has been reported at' a molecule w~ight of 
approximately 40,000 (Fulton, 1956), the demonstration of only the D 
fraction in 80% of the sera tested is not surprisi,ng. The molecular 
weight'of this fraction is around 80,000, whereas the molecular weight 
of the E fraction is 30,000. If kidney excretion of the E fragment 
is consistent with the behavior-patterns of other proteins of similar 
molecular weight, a clearance from the blood stream of the E fraction 
by the kidney would be predicted and expected. It is interesting to 
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note that the seI1um samples containi,ng, both the D and E fI1,agments 
weI1e collected fI10m patients havi,ng' a' histoI1Y of I1enal disease. 
A modified fibI1iD:ogen'assay was used to cOI1I1elate incI1eased 
levels of plasma fibrinogen with the pI1esence of fibI1inogen 
pI1oteolytic pI10ducts in the seI1um, wheI1eas the euglobulin lysis time 
was employed to cOI1I1elate incI1eased fiPI1inolytic activity with the 
pI1esence of degI1adation products in the serum. The lack of patient 
mateI1ial pI1ecl~ded an adequate evaluation of fibrinolytic activity 
and fibI1inogen levels; however, the presence of fibrinogen bI1eakdown 
pI10ducts in the serum does not'necessarily accompany incI1eased 
fibrinogen levels 011 prolonged' e,uglobulin lysis time. Only the 
plasma from one of the two-available.patients exhibited an'increased 
fiPI1inogen level and prolo,nged" e,uglobulin lysis time, 
Fresh plasma samples fI1om" the two patients just described were 
cooled to 4 C. and observed' for the appeaI1ance of a cryoprecipitate. 
CI1yoprecipitation was not evident in the plasma of either patient, 
suggesting'that in addition to incI1eased fibI1in,ogen levels and 
fibrinolytiC activity cryofibriD:0gen is not necessarily cOI1related 
with fibI1inogen breakdown'products demonstrated in the serum. 
McKee et al. (1962) studied samples of plasma from 670 
hospitalized patients. Twenty-nine patients in this study demonstrated 
a cI1yopI1ecipitate termed by' these workeI1s as cryofibI1inogen. Later 
work by' Lipinski et ale (1967). s,u.ggested that the cI1yoprecipitate is a 
soluble complex formed in-the"pI1esence of incI1eased fibI1inogen 
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bl'eakdown pl'oducts and intermediate-products formed in-the-enzymatic 
convel'sion of fibl'in,ogen- to- fibl'in.' 'The studies that> have been 
l'epol'ted on the d,egl'adation" produt!ts:-of:fibl'inolysis do not confine 
incl'eased fibl'inolytic activity,to-any single disease entity (Menon, 
1969) Ol' physiologic site. Indeed', :fibl'inolytic activity has been 
demonstl'ated to be distl'ibuted-throughout the tissue components of 
the body, with the exception of,the' liver (Todd, 1959). However, 
the greatest preponderance-of'~igestionproducts appeal's in instances 
where the liver, renal and" intravascular systems are involved. 
Doubtlessly, as further studies'areundertaken and procedures for 
studying fib~inogen bl'eakdownproducts'become more refined, the 
relationship of these products,to'specific disease entities will be 
elucidated- and the di,agnostic-,and. therapeutic implications will be 
understood. Altho,ugh current'method01:0gy for detect~ng fibrinogen 
breakdown products in the'serum-cannot.readily be employed as a 
diagnostic tool, thoseinstances-,of- bleedi,ng diathesis secondary to 
intravascular fibrinolysis' could-be'rationally and specifically 
treated if-fibrinolytic products were identified. 
SUMMARY 
1. Human fik'mogen was degraded by the addition of caamercial 
fii-rlinolytlc agents to pooled normal human plasma. Agar gel 
immunoelactropAoNs.i:a was employed to identify and cIiaracterize 
the products. resulting from the proteolytic action. Two 
products are. oliserve.d and identified. as the D and E fl'apaents. 
Tbe D fragment, represented by a band ill tIle beta are·a of tbe 
electroph.oNti:c ftald. i& formed rapidly and remains a:table. 
The & moiety is ·fOl'1ll8d at a slCMer rate and is Npztesented as 
a mgratory ))and origJinating from the locus of the D fragment 
at the onset of digestion and progressing across the electro-
ph.ONtic field to the prealbumin region. at the' caopletion of 
digestion. 
2. Gel filtration was used for the separation of the D and E 
fractions. These fractions were identified By immunoelectro-
phoretic tecb:nicque. 
3. Serum sup.lea from 199 hos.pitalized patients: were studied Dy 
immunodiffus.ion. for the presence of spontaneous fibrinolytic 
products. Tb.e. spontaneous products were detected in the serum 
of 1G of the 19i patients tested. 
'+. Immunoelectrophoresis was, employed to further characterize the 
filf,rino1ytic products occurring spontaneously in the serum of 
1Q., patients. Evidence of the D fraction was:' demonstrated in 
aQ% of the sera, whereas in 20\ of tne s'era both, the D andE 
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fracti.cm.a 1tJ8.N obaeI'ved. 
5. Fihrinogen levels, euglobulin. lysis time andczyofilrinogen 
weJ:'e determined in p-J.asma samples frail 2 of the 10 patien'ts. 
Only ene patieDt ex'fUl)lted an increased fibrinogen level and 
euglobuUn .lysis time. 
i. The clinical evaluation of tbe patient:ta . disease state was 
correla:ted in the. iDstances where fihl-inogen··breakdown products 
were present in the serum. Physiologic site. predominently 
associated with fibrinogen. breakdownpl'oducts included tbe 
li.vel". the lddney.<. and the' intravascular system. 
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